Summary & Overview

Anal and Stomal Procedures with Major Complication or Comorbidity: Inpatient Reimbursement Overview

DRG 347 encompasses inpatient admissions for anal and stomal procedures accompanied by a Major Complication or Comorbidity, reflecting a higher clinical complexity than similar procedures without such complications. This Diagnosis-Related Group matters for inpatient reimbursement because it signals greater expected resource use and higher Medicare payment relative to lower-severity groupings.

Anal and Stomal Procedures with Major Complication or ComorbidityDRG Anal and Stomal Procedures with MCCDRG 347Diagnosis-Related GroupInpatient ReimbursementMedicareColorectal SurgeryStoma RevisionFistula RepairSurgical Complications

DRG 347 Overview

DRG 347 covers inpatient admissions for anal and stomal procedures when a Major Complication or Comorbidity is present, typically including complex fistula repairs, revision of stomas, and procedures complicated by severe infection or systemic instability. These cases involve higher resource use due to extended operative time, intensive perioperative care, and increased likelihood of complications requiring additional interventions. The Diagnosis-Related Group influences Medicare payment by grouping these higher-cost admissions separately to reflect elevated expected inpatient resource consumption. Accurate clinical documentation of the Major Complication or Comorbidity is essential to classify the admission correctly for reimbursement purposes.

Clinical Trials

Randomized or prospective studies evaluating perioperative management strategies for patients undergoing complex anal and stomal procedures with major complications (MCC), such as optimization of antibiotic prophylaxis, fluid management protocols, and timing of reoperation for infected or ischemic stomas. These studies enroll adult inpatients who present with severe stoma-related complications (necrosis, deep infection, or uncontrolled sepsis) or complex anorectal pathology requiring urgent operative intervention, and compare short-term surgical morbidity, length of stay, and rates of additional procedures. Results are directly relevant to surgeons, hospitalists, and payers because they inform protocols that can reduce ICU utilization, readmissions, and costly prolonged hospital stays associated with MCC-level complications.
Comparative effectiveness trials assessing different reconstructive or diversion techniques and wound management approaches for patients with anal and stomal pathology complicated by severe tissue loss or contamination. These trials typically include patients requiring flap reconstruction, staged reoperations, or negative-pressure wound therapy versus conventional dressings, measuring wound healing, need for repeated operations, functional outcomes, and resource use. This research helps providers choose techniques that balance clinical effectiveness with resource intensity and guides payers on which approaches produce better downstream cost and utilization profiles for high-acuity DRG 347 cases.
Post-discharge observational and outcomes research focused on readmission reduction, home-stoma care, and long-term functional outcomes for survivors of anal and stomal procedures with major complications. Cohorts follow patients after hospital discharge to evaluate factors predicting 30- and 90-day readmission, ostomy-related emergency visits, quality of life, and durable independence with stoma self-care, often testing transitional-care interventions (nurse follow-up, telemedicine support). Findings are important to hospital administrators and payers because improved transitional care can lower readmissions and outpatient emergency use, thereby reducing total episode costs and improving performance on value-based metrics for this high-risk DRG.

Related Codes

383-UNCOMPLICATED-PEPTIC-ULCER-WITH-MCC

Uncomplicated Peptic Ulcer with Major Complication or Comorbidity: Inpatient Reimbursement Overview

335-PERITONEAL-ADHESIOLYSIS-WITH-MCC

Peritoneal Adhesiolysis with MCC: Inpatient Reimbursement Overview

386-INFLAMMATORY-BOWEL-DISEASE-WITH-CC

Inflammatory Bowel Disease with CC: Inpatient Reimbursement Overview

327-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITH-CC

Stomach, Esophageal and Duodenal Procedures with CC: Inpatient Reimbursement Overview

394-OTHER-DIGESTIVE-SYSTEM-DIAGNOSES-WITH-CC

Other Digestive System Diagnoses with CC: Inpatient Reimbursement Overview

375-DIGESTIVE-MALIGNANCY-WITH-CC

Digestive Malignancy with CC: Inpatient Reimbursement Overview

337-PERITONEAL-ADHESIOLYSIS-WITHOUT-CC-MCC

Peritoneal Adhesiolysis without CC/MCC: Inpatient Reimbursement Overview

381-COMPLICATED-PEPTIC-ULCER-WITH-CC

Complicated Peptic Ulcer with CC: Inpatient Reimbursement Overview

329-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITH-MCC

Major Small and Large Bowel Procedures with MCC: Inpatient Reimbursement Overview

346-MINOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITHOUT-CC-MCC

Minor Small and Large Bowel Procedures without CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 57

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.